cagrilintide semaglutide New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk cagrilintide ph – 10mg –

Online Health Assessment Complete a free consultation and health assessment from home

Inflammatory response modulation: Both peptides have been observed to affect cytokine activity and other markers of inflammation in experimental settings

Every dose fits with room to spare (4.5 mg is only 45 units), and it requires a smaller injected volume

James Greenblatt will review: Evidence-based strategies for its use Safety considerations and potential side effects Blood testing Dosing and best practices Case studies & - #PsychiatryRedefined #FunctionalPsychiatry #LowDoseLithium #NutritionalPsychiatry #FreeWebinar #LithiumOrotate To view or add a comment, sign in I'm glad to share our new retrospective cohort study in The Lancet Obstetrics, Gynaecology & Women's Health on neuropsychiatric and mental health outcomes in hyperemesis gravidarum